Article
Biochemistry & Molecular Biology
Ranjithkumar Rajendran, Vinothkumar Rajendran, Liza Gupta, Kian Shirvanchi, Darja Schunin, Srikanth Karnati, Mario Giraldo-Velasquez, Martin Berghoff
Summary: This study found that short-term treatment with IFN beta-1a can alleviate symptoms during the peak of disease in multiple sclerosis, while the combined application of IFN beta-1a and specific deletion of FGFR1 can reduce symptoms in the chronic phase. These beneficial effects may be caused by the modulation of FGFR1 rather than interferon beta-1a.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biology
Cristina-Florentina Plesa, Diana Maria Chitimus, Carmen Adella Sirbu, Monica Marilena Tantu, Minerva Claudia Ghinescu, Daniela Anghel, Florentina Ionita-Radu
Summary: This case study describes a particular association between the remission phase of multiple sclerosis and the violent onset of interferon-induced thrombotic thrombocytopenic purpura.
Article
Chemistry, Medicinal
Reinier Cardentey Sanchez, Amado Diaz de la Fe, Alejandro Pelaez Suarez, Dayme Grass, Teresa Morgado Vega, Armando Sanchez Canal, Dario Siniscalco, Maria de los Angeles Robinson Agramonte
Summary: Multiple sclerosis is an autoimmune neurodegenerative disease that lacks a curative treatment. The use of interferon beta 1a has shown safety and efficacy in treating relapsing remitting MS patients, with significant reductions in attacks, disability scale scores, and lesions observed.
DRUG DEVELOPMENT RESEARCH
(2021)
Article
Neuroimaging
Shannon Kolind, Shawna Abel, Carolyn Taylor, Roger Tam, Cornelia Laule, David K. B. Li, Hideki Garren, Laura Gaetano, Corrado Bernasconi, David Clayton, Irene Vavasour, Anthony Traboulsee
Summary: Ocrelizumab appears to protect against demyelination in multiple sclerosis patients and may provide a more favorable environment for remyelination.
NEUROIMAGE-CLINICAL
(2022)
Article
Pharmacology & Pharmacy
Francesco Piras, Lilian Arnaud, Eric Henninger, Matthew Keiser, Andrea Seitzinger, Dominic Jack, Quentin Le Masne
Summary: This study investigated adherence to, and duration of persistence with, the newest version of the RebiSmart (R) autoinjector among people with multiple sclerosis. The results showed that patients were highly adherent to using the device, and the longest persistence was observed in older individuals and males.
EXPERT OPINION ON DRUG DELIVERY
(2023)
Article
Clinical Neurology
Mark S. Freedman, Dominic Jack, Zuzana Murgasova, Milorad Todorovic, Andrea Seitzinger
Summary: The study found that patients treated with sc IFN beta-1a for relapsing MS had relatively low rates of COVID-19 infection, high recovery rates, and low rates of severe disease and death compared to the general population and other MS patients.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Juliane Klehmet, Yvonne Begus-Nahrmann, Kirsi Taipale, Gabriele Niemczyk, Karin Rehberg-Weber
Summary: This study evaluated the pregnancy outcomes of women with multiple sclerosis (MS) treated with interferon therapy. The results showed that most mothers paused interferon therapy during pregnancy and breastfeeding, and the rates of spontaneous abortions and congenital anomalies were similar to the general population. Additionally, relapse activity during pregnancy and lactation was low.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Pharmacology & Pharmacy
Paula L. L. Hyland, Lakshmi Manasa S. Chekka, Deepti P. P. Samarth, Barry A. A. Rosenzweig, Erica Decker, Esraa G. G. Mohamed, Yan Guo, Murali K. K. Matta, Qin Sun, William Wheeler, Carlos Sanabria, James L. Weaver, Sarah J. Schrieber, Jeffry Florian, Yow-Ming Wang, David G. G. Strauss
Summary: Proteomics is used to identify pharmacodynamic biomarkers for biosimilars evaluation. The study evaluated the utility of proteomic assay for interferon-beta 1a products and identified potential candidate biomarkers. This research supports clinical pharmacology studies of biosimilars with complex mechanisms or without previously characterized biomarkers.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Neurosciences
Maria Isabel Carrasco-Campos, Cristina Perez-Ramirez, Elena Macias-Cortes, Elena Puerta-Garcia, Antonio Sanchez-Pozo, Carmen Arnal-Garcia, Francisco Javier Barrero-Hernandez, Miguel Angel Calleja-Hernandez, Alberto Jimenez-Morales, Marisa Canadas-Garre
Summary: This study found that gene polymorphisms in TNFRSF10A-rs20576 and CTSS-rs1136774 have an impact on the response to IFN-beta after 24 months of treatment, while the variations in CBLB (rs12487066), OAS1 (rs10774671) or GRIA3 (rs12557782) genes do not affect individual response to IFN-beta.
MOLECULAR NEUROBIOLOGY
(2021)
Article
Clinical Neurology
Arthur Allignol, Emmanuelle Boutmy, Meritxell Sabido Espin, Kurt Marhardt, Patrick Vermersch
Summary: In this real-world setting, the effectiveness of sc IFN beta-1a does not appear to be reduced based on age. Older patients showed lower discontinuation rates and reduced disease activity, as evidenced by lower relapse rates and fewer MRI scans compared to younger patients.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L. Naylor, Li Zhu, Himanshu Naik, Cherie L. Butts
Summary: The study showed bioequivalence between intramuscular and subcutaneous administration of peginterferon beta-1a, with similar pharmacokinetic and pharmacodynamic profiles. Intramuscular administration had lower frequency of injection site reactions, and safety profiles were generally balanced between the two administration routes.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2021)
Article
Immunology
Mark S. Freedman, Jerome Wojcik, Kristina H. Holmberg, Markus Fluck, Mauro D'Antonio, Yann Hyvert, Sofia Stinchi, Vittorio D'Urso, Fernando Dangond
Summary: This study confirmed MX1, 2'5'OAS, and IL1RA as effective biomarkers for the efficacy of subcutaneous IFNβ-1a treatment, while also identifying Neopterin, TRAIL, and IP-10 as biomarkers associated with long-term treatment efficacy.
JOURNAL OF NEUROIMMUNOLOGY
(2021)
Article
Health Care Sciences & Services
Talia Piater, Mario Gietl, Stefanie Hofer, Johanna M. Gostner, Sabina Sahanic, Ivan Tancevski, Thomas Sonnweber, Alex Pizzini, Alexander Egger, Harald Schennach, Judith Loeffler-Ragg, Guenter Weiss, Katharina Kurz
Summary: Patients who had COVID-19 infection continue to experience persistent symptoms, especially in women. Immune-mediated changes in amino acid metabolism are associated with the physical level of functioning and improvements in certain symptoms.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Jeffry Florian, Victoria Gershuny, Qin Sun, Sarah J. Schrieber, Murali K. Matta, Anthony Hazel, Morasa Sheikhy, James L. Weaver, Paula L. Hyland, Cheng-Hui Hsiao, Giri Vegesna, Ryan DePalma, Aanchal Shah, Kristin Prentice, Carlos Sanabria, Yow-Ming Wang, David G. Strauss
Summary: The FDA has taken steps to enhance the development of biosimilars by providing guidance on the use of pharmacokinetic and pharmacodynamic (PD) similarity study data. In a clinical study, the potential role of PD biomarkers in biosimilar development was evaluated using interferon beta-1a and pegylated interferon beta-1a. Both PD biomarkers showed increased levels after product administration, supporting their usefulness in a PD similarity study design.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Marcello Moccia, Giuseppina Affinito, Antonio Capacchione, Roberta Lanzillo, Antonio Carotenuto, Emma Montella, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
Summary: This study demonstrates the feasibility of merging clinical registry and routinely-collected healthcare data for future multiple sclerosis research, and confirms the important role of interferon beta formulations in managing MS with positive clinical outcomes. Differences between interferon beta formulations are primarily driven by adherence and healthcare resource utilization.
Article
Health Care Sciences & Services
Rosaria De Luca, Carmela Rifici, Patrizia Pollicino, Marcella Di Cara, Sabrina Miceli, Giuseppina Sergi, Luisa Sorrenti, Michela Romano, Antonino Naro, Luana Billeri, Paola Lauria, Angelo Caminiti, Placido Bramanti, Michele Torrisi
Summary: This study aimed to investigate the effectiveness of online Skype therapy (OLST) in promoting cognitive and sensory-motor recovery in patients with severe acquired brain injury (SABI) and reducing caregiver distress. The results showed that OLST significantly reduced caregiver anxiety and burden, while improving trunk control, functional independence, cognitive functioning, and behavioral responsiveness in patients. The study also found significant changes in brain connectivity during the therapy. OLST could be a useful and complementary treatment for SABI patients and caregivers in the COVID-19 era.
JOURNAL OF TELEMEDICINE AND TELECARE
(2023)
Letter
Clinical Neurology
Emilio Portaccio, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Sherif Hamdy, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamout, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott, Roberto Bergamaschi, Rana Karabudak, Gerardo Iuliano, Chris McGuigan, Elisabetta Cartechini, Michael Barnett, Stella Hughes, Maria Jose Sa, Claudio Solaro, Ludwig Kappos, Cristina Ramo-Tello, Edgardo Cristiano, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Mark Slee, Ernest Butler, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt, Helmut Butzkueven, Julie Prevost, L. G. F. Sinnige, Jose Luis Sanchez-Menoyo, Steve Vucic, Guy Laureys, Liesbeth Van Hijfte, Dheeraj Khurana, Richard Macdonell, Riadh Gouider, Tamara Castillo-Trivino, Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso, Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Tomas Kalincik
Summary: This study evaluated the impact of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). The results showed that patients with relapsing MS who received DMT had a reduced relapse incidence, lower risk of disability worsening, and greater chance of disability improvement. The effectiveness of DMT was influenced by the severity of disability, prior relapse rate, and prior cerebral magnetic resonance imaging activity, but not by age.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Giacomo Boffa, Alessio Signori, Luca Massacesi, Alice Mariottini, Elvira Sbragia, Salvatore Cottone, Maria Pia Amato, Claudio Gasperini, Lucia Moiola, Stefano Meletti, Anna Maria Repice, Vincenzo Brescia Morra, Giuseppe Salemi, Francesco Patti, Massimo Filippi, Giovanna De Luca, Giacomo Lus, Mauro Zaffaroni, Patrizia Sola, Antonella Conte, Riccardo Nistri, Umberto Aguglia, Franco Granella, Simonetta Galgani, Luisa Maria Caniatti, Alessandra Lugaresi, Silvia Romano, Pietro Iaffaldano, Eleonora Cocco, Riccardo Saccardi, Emanuele Angelucci, Maria Trojano, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese
Summary: This study compared the effects of autologous hematopoietic stem cell transplantation (AHSCT) with other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active secondary progressive multiple sclerosis (SPMS). The results showed that AHSCT was associated with a slower disability progression and a higher likelihood of disability improvement compared to standard immunotherapy.
Article
Clinical Neurology
Lucia Campetella, Claudia Papi, Gregorio Spagni, Eleonora Sabatelli, Sara Mariotto, Matteo Gastaldi, Gianvito Masi, Sara Carta, Lara Ahmad, Francesca Rossi, Giorgia Teresa Maniscalco, Giovanna De Luca, Raffaele Iorio
Summary: This article describes a novel scoring method based on clinical and neuroimaging characteristics that predicts AQP4-IgG positivity in patients with LETM. The score has good sensitivity and specificity, which can assist clinicians in the early diagnosis and treatment of AQP4-IgG positive LETM.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
R. Veldkamp, M. D'hooge, B. M. Sandroff, J. DeLuca, D. Kos, A. Salter, A. Feinstein, M. P. Amato, G. Brichetto, J. Chataway, R. Farrell, N. D. Chiaravalloti, U. Dalgas, M. Filippi, J. Freeman, R. W. Motl, C. Meza, M. Inglese, M. A. Rocca, G. Cutter, P. Feys
Summary: Performing cognitive-motor dual tasks can negatively affect walking performance and cognitive function in individuals with progressive multiple sclerosis and cognitive impairment. This study examined the dual task performance in different disability levels and found that it significantly affected walking performance, with similar effects across disability subgroups.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Maria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, Chiara Ballerini, Mario Alberto Battaglia, Roberto Bergamaschi, Giampaolo Brichetto, S. Destan Bunul, Massimiliano Calabrese, Marco Capobianco, Paola Cavalla, Maria Grazia Celani, Marinella Clerico, Eleonora Cocco, Giancarlo Comi, Paolo Confalonieri, Antonella Conte, Cinzia Cordioli, Giovanna De Luca, Nicola De Rossi, Massimo Filippi, Haluk Gumes, Paolo Immovilli, Matilde Inglese, Rana Karabudak, Doriana Landi, Roberta Lanzillo, Maria Rita L'Episcopo, Lorena Lorefice, Vittorio Mantero, Sabrina Marangoni, Girolama Alessandra Marfia, Camilla Masciulli, Eva Milano, Lucia Moiola, Riccardo Orlandi, Francesco Patti, Paola Perini, Ilaria Pesci, Eugenio Pucci, Marco Puthenparampil, Marta Radaelli, Marco Salvetti, Arianna Sartori, Cinzia Scandellari, Sedat Sen, Aksel Siva, Silvia Strumia, Francesco Teatini, Gioacchino Tedeschi, Maria Trojano, Melih Tutuncu, Giovanna Vaula, Maria Pia Sormani, Maria Pia Amato
Summary: In this multicenter study, researchers evaluated the clinical outcomes of COVID-19 in pregnant patients with multiple sclerosis. The study found no significant increase in severe COVID-19 outcomes in multiple sclerosis patients who contracted the infection during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Review
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study aims to develop an evidence-based vaccination strategy for pwMS who are candidates for disease-modifying therapies. A multidisciplinary working group conducted a systematic literature search and formulated 53 recommendations based on the quality of evidence. The goal of this study is to homogenize immunization practices in pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Multidisciplinary Sciences
Stefano L. Benini, Erika Pellegrini, Carlo Descovich, Alessandra Lugaresi
Summary: This study explores the burden experienced by caregivers of people with Multiple Sclerosis (MS) and the resources they use to manage it. The results show that fatigue is a common experience among caregivers and they rely on both intrinsic and extrinsic resources to cope. Patient associations and the MS clinical pathway are found to be significant in supporting caregivers. The study highlights the need for caregivers to balance work and care, prioritize self-care, and have opportunities to share their experiences with others.
Article
Clinical Neurology
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S. Freedman, Harold Atkins, Joachim Burman, Jennifer Massey, Ian Sutton, Barbara Withers, Richard Macdonell, Andrew Grigg, Oivind Torkildsen, Lars Bo, Anne Kristine Lehmann, Eva Kubala Havrdova, Eva Krasulova, Marek Trneny, Tomas Kozak, Anneke van der Walt, Helmut Butzkueven, Pamela McCombe, Olga Skibina, Jeannette Lechner-Scott, Barbara Willekens, Elisabetta Cartechini, Serkan Ozakbas, Raed Alroughani, Jens Kuhle, Francesco Patti, Pierre Duquette, Alessandra Lugaresi, Samia J. Khoury, Mark Slee, Recai Turkoglu, Suzanne Hodgkinson, Nevin John, Davide Maimone, Maria Jose Sa, Vincent van Pesch, Oliver Gerlach, Guy Laureys, Liesbeth Van Hijfte, Rana Karabudak, Daniele Spitaleri, Tunde Csepany, Riadh Gouider, Tamara Castillo-Trivino, Bruce Taylor, Basil Sharrack, John A. Snowden
Summary: This study compared the effectiveness of autologous hematopoietic stem cell transplant (AHSCT) with fingolimod, natalizumab, and ocrelizumab in treating relapsing-remitting multiple sclerosis (MS). The results showed that AHSCT was more effective than fingolimod and natalizumab in preventing relapses and facilitating recovery from disability. AHSCT had similar effectiveness to ocrelizumab.
Article
Clinical Neurology
Susanna Asseyer, Nasrin Asgari, Jeffrey Bennett, Omer Bialer, Yolanda Blanco, Francesca Bosello., Anna Camos-Carreras., Edgar Carnero Contentti., Sara Carta, John Chen, Claudia Chien, Mashina Chomba, Russell C. Dale, Josep Dalmau, Kristina Feldmann, Eoin P. Flanagan, Caroline Froment Tilikete, Carolina Garcia-Alfonso, Joachim Havla, Mark Hellmann, Ho Jin Kim, Philipp Klyscz, Frank Konietschke, Chiara La Morgia, Marco Lana-Peixoto, Maria Isabel Leite, Netta Levin, Michael Levy, Sara Llufriu, Pablo Lopez, Itay Lotan, Alessandra Lugaresi, Romain Marignier, Sara Mariotto, Susan P. Mollan, Cassandra Ocampo, Frederike Cosima Oertel, Maja Olszewska, Jacqueline Palace, Lekha Pandit, Jose Luis Peralta Uribe, Sean Pittock, Sudarshini Ramanathan, Natthapon Rattanathamsakul, Albert Saiz, Sara Samadzadeh, Bernardo Sanchez-Dalmau, Deanna Saylor, Michael Scheel, Tanja Schmitz-Huebsch, Jemal Shifa, Sasitorn Siritho, Pia S. Sperber, Prem S. Subramanian, Alon Tiosano, Adi Vaknin-Dembinsky, Alvaro Jose Mejia Vergara, Adi Wilf-Yarkoni, Luis Alfonso Zarco, Hanna G. Zimmermann, Friedemann Paul, Hadas Stiebel-Kalish
Summary: This is a global study aimed at investigating the effect of early high-dose corticosteroid treatment on optic neuritis. The study will collect various data to evaluate treatment strategies and the accuracy of diagnostic criteria.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Serena Caselli, Loredana Sabattini, Davide Cattaneo, Johanna Jonsdottir, Giampaolo Brichetto, Stefania Pozzi, Alessandra Lugaresi, Fabio La Porta
Summary: This study evaluated the measurement characteristics of the BBS in Multiple Sclerosis using Rasch analysis. The results showed that the BBS-MS has good internal construct validity and reliability, making it a suitable tool for assessing balance, particularly in individuals with advanced walking disability.
FRONTIERS IN NEUROLOGY
(2023)
Retraction
Integrative & Complementary Medicine
Sabrina Giacoppo, Renato Iori, Patrick Rollin, Placido Bramanti, Emanuela Mazzon
BMC COMPLEMENTARY MEDICINE AND THERAPIES
(2023)
Article
Psychology, Clinical
Marta Bassi, Luca Negri, Sabina Cilia, Monica Falautano, Monica Grobberio, Claudia Niccolai, Marianna Pattini, Erika Pietrolongo, Maria Esmeralda Quartuccio, Rosa Gemma Viterbo, Beatrice Allegri, Maria Pia Amato, Miriam Benin, Giovanna De Luca, Claudio Gasperini, Eleonora Minacapelli, Francesco Patti, Maria Trojano, Antonella Delle Fave
Summary: This study aimed to investigate the sense of coherence among caregiving partners of PwMS and its relationship with perceived social support and illness beliefs. The results showed that perceived support from family and beliefs concerning illness-related emotional representations, illness coherence, and treatment control significantly predicted participants' sense of coherence.
REHABILITATION PSYCHOLOGY
(2023)
Review
Integrative & Complementary Medicine
Giuseppa Maresca, Vanessa Nocito, Viviana Lo Buono, Desiree Latella, Marcella Di Cara, Caterina Formica, Lara Carnazza, Edoardo Sessa, Placido Bramanti, Francesco Corallo
Summary: This study conducted a systematic review on the symptoms of people with multiple sclerosis (MS), and found that hypnosis therapy has positive impacts on reducing pain, improving psychological well-being, and relieving fatigue in MS patients. Other nonpharmacological techniques did not have the same effects.
ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
(2023)